Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
Obesity or OverweightA Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
* Adults ≥ 18 years of age.
* BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27 kg/m2 and have a current diagnosis of at least 1 of the following weight-related comorbidities (treated or untreated):
(i) Hypertension (ii) Dyslipidemia or hyperlipidemia (iii) CV disease (iv) Obstructive sleep apnea
* A stable body weight for 3 months prior to Screening (± 5% body weight change).
Exclusion Criteria:
* Have obesity induced by other endocrine disorders, such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome.
* Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening.
* Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier).
* History of type 1 diabetes mellitus or type 2 diabetes mellitus.
* Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper GI tract.
* History of acute or chronic pancreatitis.
Study Location
Research Site
Research SiteVictoria, British Columbia
Canada
Contact Study Team
Research Site
Research SiteHamilton, Ontario
Canada
Contact Study Team
Research Site
Research SiteSurrey, British Columbia
Canada
Contact Study Team
Research Site
Research SiteHamilton, Ontario
Canada
Contact Study Team
Research Site
Research SiteTerrebonne, Quebec
Canada
Contact Study Team
Research Site
Research SiteHalifax, Nova Scotia
Canada
Contact Study Team
Research Site
Research SiteToronto, Ontario
Canada
Contact Study Team
Research Site
Research SiteCalgary, Alberta
Canada
Contact Study Team
Research Site
Research SiteGuelph, Ontario
Canada
Contact Study Team
Research Site
Research SiteToronto, Ontario
Canada
Contact Study Team
- Study Sponsored By
- AstraZeneca
- Participants Required
- More Information
- Study ID:
NCT06579092